The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.
 
Zhi Peng
No Relationships to Disclose
 
Tianshu Liu
No Relationships to Disclose
 
Jia Wei
No Relationships to Disclose
 
Airong Wang
No Relationships to Disclose
 
Yifu He
No Relationships to Disclose
 
Liuzhong Yang
No Relationships to Disclose
 
Xizhi Zhang
No Relationships to Disclose
 
Nan-Feng Fan
No Relationships to Disclose
 
Suxia Luo
No Relationships to Disclose
 
Jifang Gong
No Relationships to Disclose
 
Zhen Li
No Relationships to Disclose
 
Kangsheng Gu
No Relationships to Disclose
 
Jin Wei LU
No Relationships to Disclose
 
Jianming Xu
No Relationships to Disclose
 
Qingxia Fan
No Relationships to Disclose
 
Rui-hua Xu
No Relationships to Disclose
 
Liangming Zhang
No Relationships to Disclose
 
Jianmin Fang
Employment - RemeGen; RemeGen (I)
Leadership - RemeGen
Stock and Other Ownership Interests - RemeGen
Research Funding - RemeGen
Patents, Royalties, Other Intellectual Property - RemeGen
 
Yi Ba
No Relationships to Disclose
 
Lin Shen
No Relationships to Disclose